EMA Withdrawn: Clopidogrel Acino Pharma GmbH (clopidogrel) — Acino Pharma GmbH

View source ↗

Summary

Clopidogrel product from Acino Pharma GmbH has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Status: Withdrawn. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Acino Pharma GmbH. Decision date: 13/02/2012